This study was supported by the Genome Tagging Project and grants from the National Natural Science Foundation of China (32488101, 32370909, 32293231, 32470632, 32030029, and 92253302), the National Key R&D Program of China (2024YFA1800010), the CAS Strategic Priority Research Program B (XDB0990000), the Shanghai Municipal Science and Technology Major Project (23HC1401000), the National Science and Technology Innovation 2030 Major Project of China (2023ZD0500502 and 2021ZD0203900), and by the Medical Research Council of the UK (MR/T003162/1 to I.C.)
Fortified with stabilized vitamin C and vitamin E to provide antioxidant protection against UV rays, free radicals and harmful environmental factors
Female sexual desire disorder (clinical) PT-141 FDA-approved for HSDD in premenopausal women with defined efficacy from Phase 3 pivotal trials Melanocortin receptor pharmacology research Melanotan-2 Non-selective agonist profile allows study of MC1R through MC5R activation and multi-system melanocortin signaling Sexual function with regulatory backing PT-141 Only melanocortin-based sexual function treatment with FDA approval and standardized prescription dosing Melanogenesis and tanning research Melanotan-2 Higher MC1R agonist activity produces more robust melanogenesis than PT-141, which was optimized away from tanning effects Continue Your Research Get comparison updates We publish new head-to-head comparisons regularly
This supplement should not be used as a substitute for a varied diet and healthy lifestyle
Sarcopenia The European Working Group on Sarcopenia in Older People (EWGSOP) describe a triad for sarcopenia diagnosis: (1) low muscle strength, (2) low muscle quantity/quality, and (3) low physical performance
PMID 10548966